Shorter pelvic radiation with HDR boost for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a shorter course of radiation therapy (hypofractionated whole-pelvis radiation) combined with a high-dose-rate (HDR) brachytherapy boost for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach controls cancer while possibly reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of prostate cancer.
- Your cancer must be high-risk or unfavorable intermediate-risk (based on tumor stage, Gleason score, or PSA level).
- You should not have had radiation therapy to the pelvic area before.
- You cannot have inflammatory bowel disease, active connective tissue disorders, or be on blood thinners.
- You must be willing to have a rectal spacer (a gel placed between the prostate and rectum to protect the rectum during treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
This trial tests a focused form of radiation placed inside the prostate to treat only the cancer area in people with low-risk prostate cancer. It aims to control the cancer while limiting treatment to a smaller area.
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
This study is testing a new way of giving radiation for prostate cancer, called ePUHRT, combined with a standard brachytherapy boost (a small radioactive implant placed inside the prostate). It aims to see if this approach is well-tolerated and safe for people with higher-risk prostate cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.